DENV2 Env Specific Neutra™ Antibody Products

Are you grappling with the challenges of dengue virus research, such as viral heterogeneity, antibody-dependent enhancement (ADE) concerns, or the lack of potent and specific neutralizing tools? Creative Biolabs' DENV2 Envelope (Env) Specific Neutra™ Antibody Products empower your research with high-precision, functionally validated antibodies engineered through advanced protein engineering and epitope-focused design, enabling definitive viral neutralization studies and accelerating therapeutic and vaccine development.

Introduction to DENV2 Envelope Glycoprotein

The Dengue virus-2 envelope glycoprotein (DENV2 Env) is a pivotal structural component and the primary target for neutralizing antibodies. As a class II viral fusion protein, it orchestrates host cell receptor binding and membrane fusion, making it central to viral entry and infectivity. DENV2 Env is a ~495 amino acid glycoprotein displayed as 90 homodimers on the surface of the mature virion. It is a major determinant of serotype-specific immunity and viral pathogenicity.

• Structural Insights

The protein comprises three domains: Domain I (DI), the central structural domain; Domain II (DII), containing the conserved fusion loop; and Domain III (DIII), implicated in receptor binding. Cryo-EM structures reveal that neutralizing antibodies often target epitopes on DIII or quaternary epitopes spanning adjacent Env dimers, locking them in a pre-fusion conformation and blocking membrane fusion.

Fig.1 Molecular representations of virion structures.¹

• Resistance and Signaling Pathways

Dengue infection modulates host immune signaling, including type I interferon (IFN) response evasion and inflammasome activation. The phenomenon of ADE, where subneutralizing antibodies from a prior infection enhance subsequent heterotypic infection via Fcγ receptor-mediated uptake, is a major research and therapeutic challenge directly linked to Env-antibody interactions.

• Clinical Impact

Dengue virus, primarily transmitted by Aedes mosquitoes, causes a spectrum of diseases from mild dengue fever to severe, life-threatening dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS). DENV2 is frequently associated with severe outbreaks.

• Antibodies Against DENV2 C Protein
  Potent neutralizing antibodies targeting DENV2 Env are critical reagents for:
  • Mapping conformational and linear neutralizing epitopes.
  • Studying the structural basis of virus neutralization and ADE.
  • Developing serotype-specific diagnostics and assessing vaccine immunogenicity.
  • Serving as blueprints for therapeutic monoclonal antibody (mAb) development.

Applications of Anti-DENV2 Env Neutralizing Antibodies

Fig.2 Pathogenic mechanisms and antibody-mediated enhancement of dengue virus provide the basis for the development of therapeutic monoclonal antibodies (mAbs).²

• Development and Validation of Therapeutic Candidates

High-potency anti-DENV2 Env neutralizing antibodies are leading candidates for therapeutic intervention. They directly block viral attachment and entry into host cells. In preclinical models, such antibodies have demonstrated efficacy in reducing viremia and preventing severe disease. Our Neutra™ antibodies provide essential tools for in vitro and in vivo efficacy screening, ADE risk assessment, and mechanism-of-action studies, de-risking the early-stage therapeutic pipeline.

• Vaccine Efficacy and Immunogenicity Assessment

Evaluating the quality of vaccine-induced immune responses requires precise tools. Our anti-DENV2 Env antibodies are indispensable for developing neutralization assays to quantify vaccine-elicited neutralizing titers. Furthermore, they are used in competitive ELISA or epitope mapping assays to characterize the specificity of the polyclonal response, determining if vaccination elicits antibodies against desirable, protective epitopes rather than those associated with ADE.

• Advanced Diagnostic Assay Development

Specific anti-DENV2 Env antibodies enable the development of rapid, serotype-discriminatory diagnostic tests. Utilizing pairs of our high-affinity antibodies in antigen-capture ELISA or lateral flow formats allows for the specific detection of DENV2 NS1 antigen or virions in clinical samples, facilitating early diagnosis, appropriate patient management, and effective outbreak surveillance.

Our Anti-DENV2 Env Neutralizing Antibodies

Creative Biolabs delivers a suite of premium antibodies designed for the most demanding dengue research:

• Elevated Specificity and Affinity: Thoroughly validated to ensure exclusive binding to DENV2 Env, with no cross-reactivity to other dengue serotypes or flaviviruses, yielding clear and definitive results.
• Enhanced Neutralizing Potency: Chosen and engineered for optimal neutralization effectiveness, as demonstrated in standardized cell-based infectivity assays.
• Epitope-Specific Characterization: Antibodies are characterized based on their binding domains, facilitating focused research into neutralization mechanisms and antibody-dependent enhancement (ADE).
• Validated for Various Applications: Consistent performance is assured in essential techniques, including ELISA, Western Blot, Immunofluorescence, and Neutralization Assays.

With more than twenty years of specialized experience in virology and antibody design, Creative Biolabs stands as your reliable collaborator in infectious disease research. We combine deep scientific knowledge with a commitment to delivering reproducible, high-performance reagents. Our DENV2 Env Specific Neutra™ Antibody Products are more than just reagents; they are precision tools engineered to accelerate your path from discovery to development. Reach out to our scientific team today to explore how our antibodies can enhance your dengue research initiatives.

References

1. Young, Ellen, et al. "A live dengue virus vaccine carrying a chimeric envelope glycoprotein elicits dual DENV2-DENV4 serotype-specific immunity." Nature Communications 14.1 (2023): 1371. Distributed under Open Access license CC BY 4.0, without modification. Doi: https://doi.org/10.1038/s41467-023-36702-x
2. Sarker, Animesh, Nidhi Dhama, and Rinkoo Devi Gupta. "Dengue virus neutralizing antibody: a review of targets, cross-reactivity, and antibody-dependent enhancement." Frontiers in immunology 14 (2023): 1200195. Distributed under Open Access license CC BY 4.0, without modification. Doi: https://doi.org/10.3389/fimmu.2023.1200195